Allient Q3 2026 Earnings: Record Margins Drive Profit Growth

Allient (Nasdaq: ALNT) reported Q3 2026 revenue of $164.4 million, up 18% from $138.7 million, while diluted EPS rose to $0.91 from $0.39. Gross-margin expansion and operating leverage drove profit growth well above the revenue increase, while record orders pushed backlog to $351.5 million.

Core Earnings Data

Higher volume, favorable product mix, and operational improvements under the Simplify to Accelerate NOW program lifted gross margin by 330 basis points. Operating expenses increased to $37.9 million from $34.0 million, but declined as a share of revenue by 150 basis points to 23.0%; restructuring and realignment costs also fell to $15,000 from $0.8 million.

These factors helped operating income and net income grow substantially faster than revenue.

Reported revenue faced a $0.9 million unfavorable currency effect. Excluding currency movements, organic revenue increased 19.1% on a constant-currency basis.

Business and Market Performance

Industrial remained Allient’s largest market, while Aerospace & Defense produced the fastest growth. Vehicle revenue also increased materially, although part of that growth came from shipments accelerated ahead of a customer’s model changeover.

Distribution channel sales, which represent a smaller portion of total revenue, increased 39% on broad-based channel growth. Sales to U.S. customers remained 57% of total revenue, unchanged from the prior-year quarter.

Record Orders and Backlog Improve Revenue Visibility

Orders grew considerably faster than reported revenue, producing a book-to-bill ratio of 1.33x. Management said Industrial and Aerospace & Defense led the increase, with most backlog expected to convert into revenue within six to twelve months.

The longer backlog partly reflects revised customer ordering patterns intended to secure critical materials. It improves visibility into Q4 2026 and early 2027, but the timing of customer schedules and the company’s ability to execute against the backlog will determine when those orders become revenue.

Profitability, Cash Flow, and the Balance Sheet

Operating margin reached 13.6% as gross-margin gains, expense leverage, and lower restructuring costs reinforced one another. Lower average debt also reduced quarterly interest expense by 27% to $2.5 million, providing an additional benefit below operating income.

Cash conversion did not improve at the same pace as earnings. Net cash from operating activities for the first nine months of 2026 was $22.1 million, down from $43.1 million a year earlier, primarily because of accounts-receivable timing and inventory investments supporting growth and strategic purchases of critical materials. Over the same period, capital expenditures rose to $10.6 million from $5.1 million as Allient invested in capacity, technology, and productivity.

At September 30, 2026, cash and cash equivalents were $39.6 million, compared with $40.7 million at the end of 2025. Total debt declined by $7.0 million to $173.4 million, while net debt was $133.7 million. The leverage ratio improved to 1.49x from 1.82x, and the company had $162.0 million of unused revolving credit capacity.

2026 Guidance

Allient’s quantitative outlook covers capital spending, restructuring costs, and its effective tax rate. The company did not provide prior ranges for comparison in the supplied release.

Management’s View

Chairman and CEO Dick Warzala attributed the quarter’s profitability gains to higher volume, favorable mix, and continued operating improvements under STAN. Management plans to support internal growth opportunities with investments in capacity, technology, and productivity while maintaining discipline over spending.

The company is prioritizing higher-value Motion, Controls, and Power applications in its targeted markets. Management also acknowledged that customer schedules, product mix, and the trade environment could create quarterly variability despite the stronger order and backlog position.

Recent Insider Transactions

The supplied six-month insider summary reports 15,835 shares purchased across 14 transactions and 70,457 shares sold across two transactions, resulting in net sales of 54,622 shares. The latest records include sales, stock awards, and gifts; awards and gifts do not represent open-market purchases or sales.

All ten transactions were reported as direct holdings. The data does not establish a reason for the two sales, so no conclusion about insiders’ outlook can be drawn from them alone.

Risks Investors Should Watch

• Working-capital pressure: Nine-month operating cash flow declined despite higher net income because receivables timing and inventory investments absorbed cash. Continued growth could require additional working capital before backlog converts into cash.
• Backlog conversion timing: Most backlog is expected to convert within six to twelve months, but customer schedules, program timing, and product mix can shift revenue between quarters.
• Supply and trade conditions: Strategic purchases of critical materials indicate ongoing attention to supply constraints, while management identified the trade environment as a source of quarterly variability.
• Uneven end-market demand: Medical revenue declined as weakness in mobility applications offset surgical precision motion growth, while part of Vehicle’s increase came from shipments accelerated ahead of a model changeover.

Summary

Allient’s Q3 2026 results combined double-digit revenue growth with substantially faster profit expansion as volume, mix, STAN improvements, and operating leverage lifted margins. Record orders and backlog support near-term visibility, but backlog execution and working-capital conversion remain central considerations as the company invests to support higher activity.